Decline in sales expected at $NOVN (-0,1%)

Novartis AG $NOVN (-0,1%) is expected to report a decline in quarterly sales when it presents its results for the period ending June 30, 2024 on July 18.

The Basel-based company is expected to report a 9.2% decline in sales to $12.362 billion, compared with $13.62 billion a year ago, according to the median estimate of 10 analysts, based on LSEG data. (Revenue is equal to net sales)

LSEG's mean analyst estimate for Novartis AG is earnings of $1.87 per share.

The current average analyst rating on the stock is Buy with 13 Strong Buy, 13 Hold and 2 Strong Sell recommendations.

The average analysts' earnings estimate has fallen by around 1.0% in the last three months.

The median 12-month Wall Street price target for Novartis AG is CHF 103.00, which is above the last closing price of CHF 99.10.

Hold 16 shares myself, with ~19% price gain and bissel dividend. Stay invested. No matter how the world turns - pharma is always relevant in my opinion.

Happy investing

GG

Source:

Reuters